Molecular considerations
Where standard pathways are limited, broad molecular evaluation may occasionally identify findings worth discussing.
Rare Cancers
Rare and Difficult-to-Treat Cancers
Rare tumours, cancers of unknown primary and treatment-refractory disease often benefit from careful, deliberate characterisation.
The Precision Oncology approach
Clinical history, pathology, imaging and — where appropriate — molecular findings are reviewed together, so that treatment options can be discussed in the context of this individual tumour rather than the diagnosis alone.
Treatment considerations
Treatment options depend on stage, prior therapy, performance status, pathology and molecular findings. Options are discussed individually; nothing on this page is a treatment recommendation.
When molecular testing may be useful
Molecular testing may be considered when the result could realistically influence a treatment decision, when disease is advanced or recurrent, when the diagnosis is unclear, or when eligibility for a targeted approach or clinical trial is being assessed.
Precision Longevity Program
by Dr AV Institute
Cancer Survivorship & Long-Term Health
Cancer care does not necessarily end when active treatment finishes. Survivorship care may address long-term treatment effects, cardiovascular and metabolic health, bone health, nutrition, function and appropriate cancer surveillance. It works alongside the follow-up arranged by the treating team.
Explore Cancer SurvivorshipQuestions
Common questions about rare and difficult-to-treat cancers
Rare tumours, cancers of unknown primary and treatment-refractory disease often benefit from careful, deliberate characterisation.
Where standard pathways are limited, broad molecular evaluation may occasionally identify findings worth discussing.
Depending on the clinical situation, these may include Tumour-agnostic markers (MSI-H, TMB, NTRK), Fusion events, Broad genomic profiling. Which of them are relevant is decided case by case, not routinely for everyone.
Molecular testing may be considered when the result could realistically influence a treatment decision, when disease is advanced or recurrent, when the diagnosis is unclear, or when eligibility for a targeted approach or clinical trial is being assessed.
Treatment options depend on stage, prior therapy, performance status, pathology and molecular findings. Options are discussed individually; nothing on this page is a treatment recommendation.
Discuss rare and difficult-to-treat cancers with the institute.
Bring your existing reports — reviewing them is usually the right first step.